KR101828972B1 - Manufacturing Method for Liquid Type Product Comprising Seed Oil of Korean Raspberry - Google Patents
Manufacturing Method for Liquid Type Product Comprising Seed Oil of Korean Raspberry Download PDFInfo
- Publication number
- KR101828972B1 KR101828972B1 KR1020150044266A KR20150044266A KR101828972B1 KR 101828972 B1 KR101828972 B1 KR 101828972B1 KR 1020150044266 A KR1020150044266 A KR 1020150044266A KR 20150044266 A KR20150044266 A KR 20150044266A KR 101828972 B1 KR101828972 B1 KR 101828972B1
- Authority
- KR
- South Korea
- Prior art keywords
- seed oil
- brambled
- liquid product
- oil
- brambly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000015112 vegetable and seed oil Nutrition 0.000 title claims abstract description 67
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 8
- 239000007788 liquid Substances 0.000 title claims description 3
- 235000011034 Rubus glaucus Nutrition 0.000 title 1
- 244000235659 Rubus idaeus Species 0.000 title 1
- 235000009122 Rubus idaeus Nutrition 0.000 title 1
- 239000012263 liquid product Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 8
- 230000001804 emulsifying effect Effects 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 235000017848 Rubus fruticosus Nutrition 0.000 claims description 7
- 235000019198 oils Nutrition 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- -1 fatty acid ester Chemical class 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 238000004945 emulsification Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims 2
- 241001092459 Rubus Species 0.000 claims 1
- 238000007670 refining Methods 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 abstract description 23
- 235000013376 functional food Nutrition 0.000 abstract description 11
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract description 8
- 235000021122 unsaturated fatty acids Nutrition 0.000 abstract description 8
- 150000004670 unsaturated fatty acids Chemical class 0.000 abstract description 8
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 abstract description 7
- 229940108924 conjugated linoleic acid Drugs 0.000 abstract description 7
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 abstract description 7
- 235000020665 omega-6 fatty acid Nutrition 0.000 abstract description 5
- 229940033080 omega-6 fatty acid Drugs 0.000 abstract description 5
- 239000007901 soft capsule Substances 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 6
- 244000172730 Rubus fruticosus Species 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 239000003708 ampul Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 4
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 4
- 235000019345 sodium thiosulphate Nutrition 0.000 description 4
- 108010078321 Guanylate Cyclase Proteins 0.000 description 3
- 102000014469 Guanylate cyclase Human genes 0.000 description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 229920000223 polyglycerol Polymers 0.000 description 3
- 235000005875 quercetin Nutrition 0.000 description 3
- 229960001285 quercetin Drugs 0.000 description 3
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Chinese gallotannin Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000031915 positive regulation of coagulation Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- CABVTRNMFUVUDM-SJBCKIPMSA-N 3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-SJBCKIPMSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000093727 Berzelia alopecuroides Species 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 241000238578 Daphnia Species 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 206010014523 Embolism and thrombosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010059484 Haemodilution Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000002529 Muntingia calabura Species 0.000 description 1
- 235000003886 Muntingia calabura Nutrition 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- XFZJEEAOWLFHDH-RBYKNZBFSA-N Procyanidin B4 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@@H]1c1c(O)cc(O)c3c1O[C@H]([C@@H](O)C3)c1cc(O)c(O)cc1)c(O)cc(O)c2 XFZJEEAOWLFHDH-RBYKNZBFSA-N 0.000 description 1
- 235000011552 Rhamnus crocea Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 244000111388 Rubus occidentalis Species 0.000 description 1
- 235000003942 Rubus occidentalis Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- LDKDGDIWEUUXSH-UHFFFAOYSA-N Thymophthalein Chemical compound C1=C(O)C(C(C)C)=CC(C2(C3=CC=CC=C3C(=O)O2)C=2C(=CC(O)=C(C(C)C)C=2)C)=C1C LDKDGDIWEUUXSH-UHFFFAOYSA-N 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 229920001968 ellagitannin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 229920002824 gallotannin Polymers 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940107702 grapefruit seed extract Drugs 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003129 oil well Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical class [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- XFZJEEAOWLFHDH-VUGKQVTMSA-N procyanidin B4 Chemical compound C1([C@@H]2[C@@H](O)[C@@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=CC(O)=C3C[C@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-VUGKQVTMSA-N 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/02—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by the production or working-up
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Botany (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
Abstract
본 발명은 복분자 종자유 함유 연질캅셀의 제조 방법에 관한 것이다. 보다 상세하게는 복분자 종자유를 채유하는 단계와, 복분자 종자유를 정제하는 단계와, 복분자 종자유를 유화시켜 액상제품으로 만드는 단계로 구성된다.
본 발명의 복분자 종자유에는 불포화지방산인 오메가-3, 오메가-6 지방산, 공액리놀레산이 함유되어 있어 혈행개선용 기능성식품으로 제공할 수 있다.The present invention relates to a method for producing a soft capsule containing brambly seed oil. More specifically, the method comprises the steps of extracting brambled seed oil, purifying the brambled seed oil, and emulsifying the brambled seed oil into a liquid product.
The brambled seed oil of the present invention contains omega-3, omega-6 fatty acid and conjugated linoleic acid, which are unsaturated fatty acids, and can be provided as a functional food for improving blood circulation.
Description
본 발명은 복분자 종자유 함유 액상제품의 제조 방법에 관한 것이다. 보다 상세하게는 복분자 종자유를 채유하는 단계와, 복분자 종자유를 정제하는 단계와, 복분자 종자유를 유화시켜 액상제품으로 만드는 단계로 구성된다.The present invention relates to a method for producing a liquid product containing brambly seed oil. More specifically, the method comprises the steps of extracting brambled seed oil, purifying the brambled seed oil, and emulsifying the brambled seed oil into a liquid product.
본 발명의 복분자 종자유에는 불포화지방산(Unsaturated Fatty Acids)인 오메가-3와 오메가-6 지방산 및 공액리놀레산 등이 함유되어 있어 혈행개선용 기능성식품으로 제공할 수 있다.The brambled seed oil of the present invention contains omega-3, omega-6 fatty acids and conjugated linoleic acid, which are Unsaturated Fatty Acids, and can be provided as a functional food for improving blood circulation.
복분자(black raspberry)는 장미과에 속하는 다년생의 낙엽 관목인 복분자 딸기나무의 열매다. 우리나라에는 전라북도 지역이 주요산지로 알려져 있다. 복분자는 초여름에 검붉은 열매를 수확하여 식용 또는 한방용은 강장제, 강정제, 간 보호, 신체허약, 양위, 유정 및 유뇨 등에 사용되고 있다. 복분자에 함유된 성분 중, 줄기에는 epicatechin, catechine, procyanidin B-4가 있다고 알려져 있으며, 잎에는 kaempferol, quercetin, 쿼세틴 3-O-β-D-glucuronoide, ellagic acid, 및 sanguin H-5 등이 존재한다. 또한 복분자 열매로부터는 퀘세틴 및 페놀 화합물이 존재한다. 또한 미성숙과에도 페놀 화합물로 gallotannin, 엘라기탄닌, gallic acid, 및 2,3-(S)-HHDP-D-글루코피라노사이드가 존재한다. 한편 복분자씨에서 추출한 성분이 공액리놀레산을 비롯한 오메가-3, 오메가-6, ellagitannins, 엘라그산, 팔미트산, 스테아르산 및 올레산 등의 활성 성분을 함유하고 있다는 것을 알게 되었다. 또한 복분자씨유는 혈행개선과 관련된 소재들의 복합체로, 오메가-3, 감마리놀렌산의 전구체인 리놀렌산, 다량의 항산화 성분이 가장 적합한 비율로 구성되어 있다. 따라서 기존의 오메가-3 혈행 개선 기능식품의 가장 큰 문제였던 불포화지방산의 산화를 방지하여 그 효과를 유지시켜 줄 수 있는 토코페롤이 함유되어 있으며, 다양한 폴리페놀 성분뿐만 아니라 공액리놀렌산 등 다수의 유효 성분들이 포함되어 있어 기존의 오메가-3제품보다 혈행 개선의 효과가 증강될 것으로 예상된다. 더욱이 본 발명자들은 2009년 복분자 착즙 후 잔류하는 복분자씨의 소재화를 위하여 복분자씨유 추출 및 성분에 대한 연구(특허출원) 결과, 오메가-3 및 오메가-6 지방산과 공액리놀레산 등 다양한 기능성 소재임을 알고 본 발명을 완성하게 되었다. Black raspberry is the fruit of the bokbunja strawberry tree, a perennial deciduous shrub belonging to the rose family. In Korea, Jeollabuk - do province is known as a major producing region. Bokbunja harvests sour red berries in the early summer and is used for edible or herbal medicine such as tonic, kangjeongje, liver protection, physical weakness, immobilization, oil well and urination. It is known that epicatechin, catechine, and procyanidin B-4 are present in the stem of the bokbunja, and kaempferol, quercetin, quercetin 3-O-β-D-glucuronoide, ellagic acid, and sanguin H-5 exist in the leaves. do. Quercetin and phenolic compounds are also present in the bokbunja fruit. In addition, immature and Edo phenolic compounds exist as gallotannin, elaarge tannin, gallic acid, and 2,3- (S) -HHDP-D-glucopyranoside. On the other hand, it was found that the ingredients extracted from bramble seeds contained active ingredients such as omega-3, omega-6, ellagitannins, elagic acid, palmitic acid, stearic acid and oleic acid including conjugated linoleic acid. In addition, bokbunja seed oil is a complex of materials related to blood circulation improvement. Omega-3, linolenic acid, a precursor of gamma linolenic acid, and a large amount of antioxidants are most suitable. Therefore, tocopherol, which can prevent the oxidation of unsaturated fatty acid, which is the biggest problem of conventional omega-3 blood circulation improving food, is contained, and various active ingredients such as conjugated linolenic acid as well as various polyphenols It is expected that the effect of blood circulation improvement will be enhanced more than the existing omega-3 products. Furthermore, the inventors of the present invention have found out that a variety of functional materials such as omega-3 and omega-6 fatty acids and conjugated linoleic acid are known as a result of a study on the extraction of the bokbunja seed oil and the study of the ingredients (patent application) Thereby completing the present invention.
혈행개선이라 함은 혈행 증진을 의미하며, 혈행 장애에 따른 혈전증 및 색전증은 심근경색, 뇌졸중 등 심각한 심혈관 질환의 원인이 되며, 잘못된 식습관 및 생활습관, 고지혈증, 고혈압, 당뇨병 등이 혈행장애를 일으키는 위험요인으로 지적되고 있다. Thrombosis and embolism due to hematological disorders are the causes of serious cardiovascular diseases such as myocardial infarction and stroke. In addition, there is a risk that blood circulation is caused by erroneous eating habits and lifestyle, hyperlipidemia, hypertension and diabetes. .
혈행 개선에는 혈장 및 혈구세포(적혈구 및 혈소판)가 주로 관여하며 혈류의 항상성을 유지하고, 혈관의 손상된 부위나 염증 부위에서 정상적인 지혈과 보호작용을 유지하며, 혈장내의 coagulation factors의 지나친 활성화, 혈소판 응집 촉진, 적혈구 변형능 이상은 혈류의 항상성을 파괴하여 혈행 장애 질환인 동맥경화, 뇌졸중 등의 심혈관계 질환이 발생하게 되어 과도한 지혈작용 및 혈괴의 생성은 혈액의 흐름을 방해하여 혈행 이상을 초래하며 혈전(thrombus)과 같은 병변을 유발한다. 따라서 이러한 혈행장애(심혈관계 질환)이 발생하여 약물을 통한 치료가 이루어지기 전에 건강기능식품의 섭취를 통한 혈행 개선은 만성 성인병 예방에 매우 중요하다. Platelet and hematopoietic cells (red blood cells and platelets) are mainly involved in blood circulation improvement. They maintain homeostasis of blood flow, maintain normal hemostasis and protection function in injured or inflamed areas of blood vessels, excessive activation of coagulation factors in plasma, And hemorrhagic diseases such as atherosclerosis and stroke are generated. Thus, excessive hemostatic action and formation of blood clogs interfere with the flow of blood, resulting in hemodilution abnormality, and blood clotting thrombus). Therefore, improvement of blood circulation through ingestion of health functional foods is very important for the prevention of chronic adult diseases before such treatment (hemodialysis) occurs.
혈행은 혈액을 구성하는 혈장 및 혈구세포가 혈류의 항상성을 유지시키며 혈관의 손상된 부위나 염증 부위에서 정상적인 지혈과 보호 작용을 유지함으로써 인체의 정상적인 기능을 유지시킨다. 그러나 혈장 내의 coagulation factors의 지나친 활성화, 혈소판 응집 촉진, 적혈구 변형능 이상은 혈류의 항상성을 파괴하여 동맥경화, 뇌졸중 등의 심혈관계 질환을 발생시킨다. 혈관의 내피세포는 혈액덩어리를 분해하는 물질을 생성하고, 혈류량 및 속도를 조절하는 중요한 부분이다. 이 내피세포가 어떤 자극에 의하여 손상을 받으면, 그 안으로 콜레스테롤이 쌓여, 플라그를 형성하게 된다. 플라그가 쌓인 혈관 부분은 부풀어 오르게 되고, 혈관이 좁아져 혈액의 흐름을 방해할 수 있다. 혈액의 흐름은 혈중 콜레스테롤, 지방, 포도당 등과 밀접한 관계가 있어 동물성 지방, 소금 등의 섭취를 줄이고 채소, 과일, 생선, 곡류 등의 섭취를 높이는 것이 혈액의 흐름에 도움을 줄 수 있다. Blood circulation maintains blood flow homeostasis of plasma and blood cells constituting blood, maintains normal function of human body by maintaining normal hemostasis and protection function in injured area or inflammation part of blood vessel. However, excessive activation of coagulation factors in the plasma, promotion of platelet aggregation, and erythrocyte deformity break down the homeostasis of blood flow, resulting in cardiovascular diseases such as arteriosclerosis and stroke. The endothelial cells of the blood vessels are substances that break down blood clots and are an important part of regulating blood flow and velocity. When this endothelial cell is damaged by some stimulus, cholesterol builds up in it and forms a plaque. The portion of the blood vessel where the plaque is piled up swells, and the blood vessel narrows, which may interfere with the flow of blood. The blood flow is closely related to blood cholesterol, fat and glucose, so reducing intake of animal fat and salt, and increasing the intake of vegetables, fruits, fish, and grains can help the flow of blood.
혈행개선을 위해서는 혈액중의 콜레스테롤 수치를 낮추거나, 혈관을 이완시켜야 하는데, HMG(3-hydroxy-3-methylglutaryl)-CoA reductase는 콜레스테롤 생합성에 중요하게 작용하는 효소로서 동맥경화 치료에 statin 계열의 약물들은 HMG-CoA reductase의 저해제로 사용하고 있다. 따라서 HMG-CoA reductase의 활성을 조절하면 혈중 콜레스테롤의 수치를 조절하여 혈행개선에 도움을 준다고 알려져 있다. 또한 혈관을 이완시키는데 있어서 일산화질소(NO)는 인체 내 신경계, 면역계, 심혈관계 등에 관여하는 매우 중요한 전령분자이다. NO는 혈관평활근 세포내의 guanylate cyclase (GC)를 자극하여 3', 5'-cyclic guanosine monophosphate (cGMP)를 증가시켜서 내피 의존적인 혈관이완을 일으킨다. sodium nitroprusside는 평활근의 Guanylate cyclase를 자극시켜 cGMP의 생성을 증가시킴으로써 혈관이완제로 작용한다.본 발명과 관련된 종래기술은 한국특허등록번호10-0650016(복분자로부터 항산화 활성 물질의 분리방법)은 복분자를 착즙하여 잔사를 얻고, 추출한 후 방향족계 흡착제를 사용하여 항산화 활성 물질을 분리한다. 한국특허공개번호 10-2012-0119265(항산화 기능성 조성물 및 이를 함유하는 기능성 식품)은 오미자, 인삼, 하수오 및 복분자를 유효성분으로 함유하고, 생지황 즙 및 꿀을 추가하여 고제로 제형화된 항산화 기능성 조성물 및 식품에 관한 것이다. 그러나 이들 종래기술은 복분자 종자유를 사용하는 본 발명과는 기술적 사상이나 기술적 구성이 다른 것이다. In order to improve blood circulation, it is necessary to lower the cholesterol level in the blood or relax the blood vessels. HMG (3-hydroxy-3-methylglutaryl) -CoA reductase is an enzyme which plays an important role in cholesterol biosynthesis. Are used as inhibitors of HMG-CoA reductase. Therefore, it is known that the activity of HMG-CoA reductase is regulated to regulate blood cholesterol level to improve blood circulation. In addition, nitrogen monoxide (NO) is a very important messenger molecule involved in nervous system, immune system, cardiovascular system, etc. in relaxing blood vessels. NO stimulates endothelium-dependent vasorelaxation by stimulating guanylate cyclase (GC) in vascular smooth muscle cells to increase 3 ', 5'-cyclic guanosine monophosphate (cGMP). sodium nitroprusside acts as a vasodilator by stimulating guanylate cyclase of smooth muscle to increase the production of cGMP. The prior art related to the present invention is Korean Patent Registration No. 10-0650016 (a method for separating an antioxidant active substance from a bokbunja) To obtain a residue, and after extraction, an antioxidative active substance is separated using an aromatic adsorbent. Korean Patent Laid-Open No. 10-2012-0119265 (antioxidant functional composition and functional food containing the same) contains omega, ginseng, daphnia and bokbunja as an active ingredient, and addition of raw persimmon juice and honey to form a high-antioxidant functional composition And foods. However, these prior arts have different technical ideas and technical configurations from the present invention using brambly seed oil.
본 발명의 목적은 복분자 유래 종자유에 함유된 불포화지방산을 이용하는 혈행개선용 건강기능식품을 제공하는 데 있다. 종래의 복분자는 과육에 포함된 기능성 성분을 이용하여 복분자주나 복분자과육 가공품을 만들어 소비자에게 제공되었으나, 복분자씨는 폐기처리되어 왔다. 본 발명은 복분자씨 오일에 함유된 불포화지방산 및 활성 성분을 이용하여 액상의 혈행개선용 건강기능식품 또는 그 조성물을 제공하는 데 있다. 종래의 혈행개선용 일반의약품은 써큐란(동아제약), 아스피린(바이엘)등에 비하여 건강기능식품은 복합성분을 함유하므로 혈행 개선 외에 다양한 효과를 나타내는 경우가 많다. 비타민E는 내분비기능 강화와 항산화작용이 있고, 은행잎제제는 귀울림증 치매예방 치료, 홍화씨유는 비만개선에 오메가3는 관절염의 항염작용과 태아의 시력 신경계통 정상발육을 원하는 임산부에게 도움을 줄 수 있다.It is an object of the present invention to provide a health functional food for improving blood circulation using an unsaturated fatty acid contained in bramble-derived seed oil. Conventional bokbunja were made by making bokbunja or bokbunja pulp processed product using functional ingredients contained in pulp, but bokbunja was discarded. The present invention is to provide a health functional food for improving blood circulation or a composition thereof by using an unsaturated fatty acid and an active ingredient contained in brambly seed oil. Conventional general medicines for blood circulation improvement have various effects besides improvement of blood circulation because health functional foods contain a complex component in comparison with Saracen (Donga Pharmaceutical) and aspirin (Bayer). Vitamin E enhances endocrine function and has antioxidant properties. Ginkgo biloba is a preventive treatment for diphtheria, and safflower oil helps to improve obesity. Omega 3 can help pregnant women who want to have arthritis anti-inflammatory activity and normal development of the fetal vision system. have.
본 발명은 복분자씨 오일에 함유된 불포화지방산 및 활성 성분을 이용하여 액상의 혈행개선용 건강기능식품 또는 그 조성물을 제공하는 데 있다.The present invention is to provide a health functional food for improving blood circulation or a composition thereof by using an unsaturated fatty acid and an active ingredient contained in brambly seed oil.
본 발명은 복분자 종자유를 채유하는 단계와, 복분자 종자유를 정제하는 단계와, 복분자 종자유를 유화시켜 액상제품으로 만드는 단계로 구성된다.The present invention relates to a method for producing a liquid product comprising extracting brambled seed oil, purifying the brambled seed oil, and emulsifying the brambled seed oil into a liquid product.
본 발명의 복분자 종자유는 불포화지방산인 오메가-3와 오메가-6 지방산 및 공액리놀레산이 함유되어 있어 혈행개선용 기능성식품으로 제공할 수 있다.The brambled seed oil of the present invention contains omega-3, omega-6 fatty acid and conjugated linoleic acid, which are unsaturated fatty acids, and can be provided as a functional food for improving blood circulation.
도 1은 본 발명의 제조공정도이다.1 is a manufacturing process diagram of the present invention.
본 발명은 복분자 종자유를 채유하는 단계와, 복분자 종자유를 정제하는 단계와, 복분자 종자유를 유화시켜 액상제품으로 만드는 단계로 구성된다.The present invention relates to a method for producing a liquid product comprising extracting brambled seed oil, purifying the brambled seed oil, and emulsifying the brambled seed oil into a liquid product.
종자유의 채유는 분리, 건조, 로스팅, 착유, 원심분리 및 여과하여 얻는다. 성분 및 함량 분석한 결과(한국기능식품연구원, 수원여대 식품분석센터) 복분자종자유의 지방산 성분 및 함량, 그 외 성분 분석을 통해 오메가-3는 23.8~33.8%, 오메가-6는 42.6~49.9% 등 함량 확인했다. 그 외 토코페놀은 8.3mg/100g, 공액리놀레산은 1.11mg/g, 총폴리페놀은 0.68mg/g, 총플라보노이드는 1.13mg/g 함량 확인되었다.Oil of seed oil is obtained by separation, drying, roasting, milking, centrifugation and filtration. Omega-3 was 23.8 ~ 33.8% and Omega-6 was 42.6 ~ 49.9% by analysis of fatty acid composition, content and other components of brambled seed oil (Korea Food Research Institute, Suwon Women's University) The content was confirmed. Other contents of tocopherol were found to be 8.3 mg / 100 g, conjugated linoleic acid was 1.11 mg / g, total polyphenol was 0.68 mg / g and total flavonoid was 1.13 mg / g.
상기에서 종자유의 정제는 탈검, 탈산 및 탈색 공정으로 이루어진다. 상기에서 종자유의 유화는 폴리글리세린지방산 에스테르로 1차유화시키는 단계와, 레시틴으로 2차유화시키는 단계와, 복분자 종자유로 3차유화시키는 단계와, 점증제인 구아검으로 4차유화시키는 단계로 구성된다. 상기에서 4차에 걸쳐 유화된 복분자 종자유를 균질하는 단계와, 부원료(7종)를 혼합하는 단계와, 재차 균질하는 단계와, 살균하는 단계로 구성된다.The purification of the seed oil is carried out by a de-oxidation, deoxidation and decolorization process. In the above, emulsification of seed oil is composed of a step of primary oiling with polyglycerol fatty acid ester, a step of secondary oiling with lecithin, a step of tertiary oiling with brambly seed oil, and a step of quaternizing oil with guanidine gum. Homogenizing the brambled seed oil emulsified in the fourth order, mixing the additive (7 kinds), homogenizing again, and sterilizing.
1) 종자유 채유 1) Seed Oil
복분자씨를 분리하여 건조한 후, 종자유를 135∼145℃에서 3∼5분간 로스팅하고, 125∼135℃에서 1∼10분간 착유하여 원심분리 및 여과한다. After the brambled seeds are separated and dried, seed oil is roasted at 135 to 145 캜 for 3 to 5 minutes, milked at 125 to 135 캜 for 1 to 10 minutes, centrifuged and filtered.
2) 종자유의 정제2) Purification of seed oil
탈검; 오일 97 중량%와 물 3 중량%를 섞어 80℃에서 교반, 4,000rpm으로 10분간 원심분리하여 복분자 종자유를 탈검한다. Defection; 97% by weight of oil and 3% by weight of water are mixed and stirred at 80 DEG C and centrifuged at 4,000 rpm for 10 minutes to observe the bacterium seed oil.
탈산; 탈검된 복분자 종자유에 NaOH 와 상기 NaOH 전체 중량의 2 중량%에 해당되는 페놀프탈렌을 혼합한 액을 첨가하여 만들어진 핑크색의 용액을 70℃ 온수로 수세후 4,000 rpm으로 10분간 원심분리(핑크색이 황색, 백색, 투명액으로 변함)하여 복분자 종자유를 탈산한다. Deoxidation; The pink solution prepared by adding NaOH and phenol phthalene corresponding to 2 wt% of the total weight of the NaOH to the decolorized bramblor seed oil was centrifuged at 4,000 rpm for 10 minutes at 70 ° C in hot water, , White, transparent liquid) to deoxidize bramble seed oil.
탈색; 탈산된 복분자 종자유에 상기 탈산된 복분자 종자유 전체 중량의 5 중량%에 해당되는 활성탄을 첨가하고 100℃로 교반한 후 원심분리하여 상층액을 얻고 이를 여과 및 탈색하여 복분자 종자유를 얻는다. decolorization; Activated carbon corresponding to 5% by weight of the total weight of the deacidized brambled seed oil is added to the deoxidized brambled seed oil, stirred at 100 ° C and centrifuged to obtain a supernatant, which is filtered and discolored to obtain brambled seed oil.
3) 상기에서 종자유의 유화 3) In the above,
증류수 7.16mL에 폴리글리세린지방산 에스테르 0.4g(4%)을 4,000rpm에서 70℃로 20분간 1차유화시키는 단계와, 레시틴 0.4g을 4,000rpm에서 70℃로 20분간 2차유화시키는 단계와, 복분자 종자유 2mL(20%)로 4,000rpm에서 70℃로 20분간 3차유화시키는 단계와, 구아검 0.04g로 4,000rpm에서 70℃로 20분간 4차유화시키는 단계로 구성된다.(4%) of polyglycerol fatty acid ester at 4,000 rpm for 20 minutes at 70 DEG C, and a step of secondary lyophilizing 0.4 g of lecithin at 4,000 rpm for 20 minutes at 70 DEG C and 2 mL of brambled seed oil (20%) at 4,000 rpm to 70 ° C for 20 minutes, and a step of quaternizing with 0.04 g of guar gum at 4,000 rpm at 70 ° C for 20 minutes.
삭제delete
<실시예 1-4>≪ Example 1-4 >
복분자 종자 10kg을 수집하여 세척, 분리, 건조, 로스팅, 착유, 원심분리 및 여과하여 복분자 종자유를 얻었다. 종자유를 탈검, 탈산 및 탈색 공정을 거쳐 정제하여 종자유 1kg을 얻었다. 10kg of bramble seeds were collected, washed, separated, dried, roasted, milked, centrifuged and filtered to obtain bramble seed oil. The seed oil was defected, deoxidized and decolorized and purified to obtain 1 kg of seed oil.
증류수 7∼7.3ml와 폴리글리세린지방산 에스테르 0.3∼0.5g를 넣고 4,000rpm에서 70℃로 1차유화시킨 후, 추가로 레시틴 0.3∼0.5g를 섞어 4,000rpm에서 70℃로 2차유화시킨다. 상기의 유화제에 복분자 종자유 1∼3ml를 섞고 4,000r에서 70℃로 20분간 3차유화시킨 후, 구아검을 0.03∼0.05ml를 첨가하여 4,000r에서 70℃로 20분간 4차유화시켰다. 7 to 7.3 ml of distilled water and 0.3 to 0.5 g of polyglycerol fatty acid ester are firstly emulsified at 4,000 rpm at 70 DEG C and then 0.3 to 0.5 g of lecithin is further mixed and emulsified at 4,000 rpm to 70 DEG C. 1 to 3 ml of brambled seed oil was mixed with the above emulsifier, and the emulsion was tertiary emulsified at 4,000 r to 70 ° C for 20 minutes. Then, 0.03 to 0.05 ml of guar gum was added and emulsified for 4 minutes at 4,000 r for 20 minutes.
상기에서 4차에 걸쳐 유화된 복분자 종자유 10ml을 70℃에서 700 bar로 균질하고, 부원료인 퍼플그레이프 0.8∼1.2ml, 프락토올리고당 4.5∼5.5ml, 구연산 0.04∼0.06ml, 유자향 0.2∼0.4ml, 블루베리향 0.2∼0.4ml, 키키체리퓨레 2.5∼3.5ml, 자몽종자추출물 0.003∼0.005ml를 혼합하였다. 재차 70℃에서 700 bar로 균질하는 단계와, 90℃에서 15분간 살균하는 단계를 거쳐 균질(유화)액을 얻었다. 복분자 종자유 유화액을 액상제품으로 하여 엠플제조기에 넣고 앰플을 만들었다.10 ml of brambled seed oil emulsified over the fourth order was homogenized at 700 ° C at 700 bar, and the amount of purple grape 0.8-1.2 ml, fructooligosaccharide 4.5-5.5 ml, citric acid 0.04-0.06 ml, citron 0.2-0.4 ml , 0.2 to 0.4 ml of blueberry flavor, 2.5 to 3.5 ml of chickberry puree, and 0.003 to 0.005 ml of grapefruit seed extract. Homogenization at 700 DEG C again at 70 DEG C and sterilization at 90 DEG C for 15 minutes yielded a homogeneous (emulsified) solution. The brambled seed oil emulsion was made into a liquid product and put into an ampule maker to make an ampoule.
<시험예 1>; 정제된 복분자 종자유의 산가 측정≪ Test Example 1 > Acid value measurement of purified brambled seed oil
시료 5~10g에 중성의 에탄올과 에테르 혼액(1:2) 100mL 마개달린 삼각플라스크 사용하여 페놀프탈레인시액 약 20㎕ 혼합(지시약) 0.1 N 에탄올성수산화칼륨용액으로 적정(엷은 홍색이 30초간 지속할 때까지)한다. Mix approximately 20 μl of phenolphthalein solution (indicator) with 5 ~ 10g of neutral ethanol and Erlenmeyer flask with 1: 2 mixture of ether (1: 2) stopper. Titrate with 0.1 N ethanolic aqueous solution of potassium hydroxide (pale red for 30 seconds .
. 산가 = . Acid value =
S : 검체의 채취량(g)S: Amount of sample (g)
a : 검체에 대한 0.1N 에탄올성 수산화칼륨용액의 소비량(mL) a: consumption of 0.1 N ethanolic potassium hydroxide solution (mL)
b : 공시험(에탄올, 에테르혼액(1:2) 100mL)에 대한 0.1N 에탄올성 수산화칼륨용액의 소비량(mL) b: Consumed amount (mL) of 0.1 N ethanolic potassium hydroxide solution to a blank test (ethanol, ether mixture (1: 2) 100 mL)
f : 0.1N 에탄올성 수산화칼륨용액의 역가 f: Potency of 0.1N ethanolic potassium hydroxide solution
상기에서 검체가 착색되어 있을 때는 지시약은 1% 티몰프탈레인, 알코올용액이나 2% 알칼리블루-6B 알코올용액을 사용하던지 또는 검체를 소량으로 하여 상기 용제를 증량하여 시험하며, 감마오리자놀이 함유된 미강유 등은 2% 알칼리블루-6B를 사용한다. 복분자유의 산가를 측정한 결과 1.0187 mg KOH/g oil로 나타났다.
When the specimen is colored, the indicator is tested by using 1% thymolphthalein, an alcohol solution or a 2% alkali blue-6B alcohol solution or by increasing the amount of the test substance by a small amount. 2% alkali blue-6B is used. The acid value of bokbunja oil was measured to be 1.0187 mg KOH / g oil.
<시험예 2>; 정제된 복분자 종자유의 과산화물가 측정 ≪ Test Example 2 > Peroxide measurement of purified brambled seed oil
시료 1~5g과 초산을 클로로포름(3:2) 25mL을 취하고 포화요오드화칼륨용액 1mL (시료와 초산을 필요에 따라 약간 가온하여 녹이면서 클로로포름을 가볍게 흔들어 섞고, 10분간 어두운 곳에 방치하고, DW 30mL 세게 흔들어 섞음고, 전분시액 1mL 혼합(지시약) 0.01 N 티오황산 나트륨액으로 적정한다.Take 1 to 5 g of the sample and 25 mL of chloroform (3: 2) as the acetic acid, add 1 mL of saturated potassium iodide solution (sample and acetic acid, slightly warmed as necessary) while gently shaking the chloroform, Shake and shake, and add 1 mL of starch solution (indicator). Titrate with 0.01 N sodium thiosulfate solution.
과산화물가 = Peroxide value =
a : 0.01 N 티오황산나트륨액의 적정수(mL) a: Titration number of 0.01 N sodium thiosulfate solution (mL)
b : 공시험에서의 0.01N 티오황산나트륨액의 소비량(mL) b: Consumed amount of 0.01 N sodium thiosulfate solution in the blank test (mL)
f : 0.01 N 티오황산나트륨액의 역가f: Potency of 0.01 N sodium thiosulfate solution
복분자 종자유의 과산화물가는 1.0107 meq/kg oil 로 나타났다.
The peroxide value of bramble seed oil was 1.0107 meq / kg oil.
<적용예 1><Application Example 1>
본 발명의 조성물을 건강기능식품법 상으로 허용하는 방법에 따라서 앰플제조기(Ampouler)를 이용하여 플라스틱계열제의 주입관에 복분자 종자유 20ml를 주입하고 상부를 밀봉하여 앰플을 만들었다.According to the method of allowing the composition of the present invention as a health functional food method, 20 ml of brambled seed oil was injected into an injection tube made of plastic material using an ampoule, and the ampoule was made by sealing the upper part.
<적용예 2>≪ Application example 2 >
적용예 1과 같은 방법으로 10ml 앰플을 만들었다.A 10 ml ampoule was prepared in the same manner as in Application Example 1.
본 발명의 복분자 종자유에는 불포화지방산인 오메가-3와 오메가-6 지방산 및 공액리놀레산이 함유되어 있어 혈행개선용 기능성식품으로 제공할 수 있으므로 산업상 이용 가능성이 있다. The brambled seed oil of the present invention contains omega-3, omega-6 fatty acids and conjugated linoleic acid, which are unsaturated fatty acids, and thus can be used as a functional food for improving blood circulation, and thus is industrially applicable.
Claims (9)
상기 복분자 종자유의 정제는 오일 97 중량%와 물 3 중량%를 섞어 80℃에서 교반한 후 4,000 rpm으로 10분간 원심분리하여 복분자 종자유를 탈검하는 단계와, 탈검된 복분자 종자유에 NaOH 와 상기 NaOH 전체 중량의 2 중량%에 해당되는 페놀프탈렌을 혼합한 액을 첨가하여 만들어진 핑크색의 용액을 70℃ 온수로 수세 후 4000 rpm으로 10분간 원심분리하여 복분자 종자유를 탈산하는 단계와, 탈산된 복분자 종자유에 상기 탈산된 복분자 종자유 전체 중량의 5 중량%에 해당되는 활성탄을 첨가하고 100℃로 교반 후 원심분리하여 상층액을 얻고 이를 여과 및 탈색하는 단계로 구성되는 것을 특징으로 하고,
상기 복분자 종자유의 유화는 폴리글리세린지방산에스테르로 1차유화시키는 단계와, 레시틴으로 2차유화시키는 단계와, 복분자 종자유로 3차유화시키는 단계와, 구아검으로 4차유화시키는 단계로 구성되는 것을 특징으로 하는 복분자 종자유를 함유한 액상제품의 제조 방법Extracting brambled seed oil; Refining the extracted brambled seed oil; Emulsifying the purified brambly seed oil into a liquid product by mixing with an additive,
The refined brambled seed oil was prepared by mixing 97 wt% of oil and 3 wt% of water and stirring at 80 캜 and then centrifuging at 4,000 rpm for 10 minutes to observe the brambled seed oil. The defatted bramblor seed oil was mixed with NaOH, And 2% by weight of phenolphthalene. The resulting pink solution was washed with hot water at 70 DEG C and then centrifuged at 4000 rpm for 10 minutes to deoxidize the brambled seed oil. Adding activated carbon corresponding to 5% by weight of the total weight of the deoxidized bramblor seed oil, stirring the mixture at 100 DEG C and centrifuging to obtain a supernatant, filtering and decolorizing the supernatant,
Wherein the emulsification of the brambled seed oil comprises a step of primary oiling with polyglycerin fatty acid ester, a step of secondary lyophilizing with lecithin, a step of trihydrating with brambly seed oil, and a step of quaternizing with gum gum. For producing a liquid product containing
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150044266A KR101828972B1 (en) | 2015-03-30 | 2015-03-30 | Manufacturing Method for Liquid Type Product Comprising Seed Oil of Korean Raspberry |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150044266A KR101828972B1 (en) | 2015-03-30 | 2015-03-30 | Manufacturing Method for Liquid Type Product Comprising Seed Oil of Korean Raspberry |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20160116489A KR20160116489A (en) | 2016-10-10 |
KR101828972B1 true KR101828972B1 (en) | 2018-02-13 |
Family
ID=57146453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150044266A Active KR101828972B1 (en) | 2015-03-30 | 2015-03-30 | Manufacturing Method for Liquid Type Product Comprising Seed Oil of Korean Raspberry |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101828972B1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101168169B1 (en) * | 2009-08-19 | 2012-07-24 | 남현수 | Rubus coreanus Miquel oil composition, use and preparation method thereof |
-
2015
- 2015-03-30 KR KR1020150044266A patent/KR101828972B1/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101168169B1 (en) * | 2009-08-19 | 2012-07-24 | 남현수 | Rubus coreanus Miquel oil composition, use and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20160116489A (en) | 2016-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9132104B2 (en) | Fortification of nutritional products with olive extracts containing hydroxytyrosol and hydroxytyrosol fortified nutritional products | |
JP2005528435A (en) | Policosanol composition, extraction from new sources, and uses thereof | |
WO2011112117A1 (en) | Premix for food products | |
AU2015329663A1 (en) | Marine lecithin preparations with enhanced oxidation resistance | |
KR101244586B1 (en) | Sesamin/episesamin compositions | |
Parmar et al. | Development of process for the production of arjuna herbal ghee from buffalo milk | |
JP6994191B2 (en) | Food and drink with Kawachi Bankan pericarp | |
US9034399B2 (en) | Dietary compositions for promoting brain health | |
JPH10276721A (en) | Astaxanthin-containing food or drink | |
KR101828972B1 (en) | Manufacturing Method for Liquid Type Product Comprising Seed Oil of Korean Raspberry | |
KR101828963B1 (en) | Manufacturing Method for Soft Capsule Product Comprising Seed Oil of Korean Raspberry | |
KR20040101694A (en) | A food containing -renolenic acid for a climacteric woman | |
JP2004323439A (en) | Composition for ameliorating blood viscosity | |
JP7075575B2 (en) | Food composition for improving lipid metabolism or suppressing hepatic lipid accumulation | |
RU2457713C2 (en) | Premix for food products | |
JP2009196967A (en) | Agent for increasing relative quantity of polyunsaturated fatty acid in blood, and pharmaceutical composition, quasi-drug, cosmetics, edible composition and animal feed containing the agent | |
RU2602608C1 (en) | Functional food products and method for production thereof | |
US20230241022A1 (en) | Transthyretin tetramer stabilizing agent, and preventing agent or progression suppressing agent for transthyretin amyloidosis | |
JP2006089387A (en) | Ameliorant for blood fluidity | |
JP2011132147A (en) | Neutral fat absorption inhibitor comprising concentrated red wine essence as effective ingredient | |
JP2006306855A (en) | Oil and fat-containing composition for suppressing carcinogenesis | |
EP3361883B1 (en) | Capsules for lowering serum cholesterol | |
Ali | Preparation and Properties of Low-Cholesterol Ghee | |
ARSHATH | EFFECT OF CURRY LEAVES (Murraya koeneigii) EXTRACT ON THE THERMAL STABILITY OF GHEE | |
KR20070095485A (en) | Food additive that shows the neuroprotective effect, which contains mixed herbal extract of licorice, wheat and control as an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20150330 |
|
PA0201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20160603 Patent event code: PE09021S01D |
|
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20161229 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20170717 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20180207 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20180207 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20211117 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20230117 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20231206 Start annual number: 7 End annual number: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20250205 Start annual number: 8 End annual number: 8 |